Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
2020;22(Suppl 1):4654
Eligibility requirements for the GLP-1 Bridge Program include: Age 18 or older Enrollment in a Medicare Part D or Medicare Advantage Prescription Drug (MA-PD) plan One of the following BMI and health condition combinations: BMI 35 (regardless of other health conditions) BMI 30 with at least one of the following: heart failure with preserved ejection fraction (HFpEF), hypertension, or chronic kidney disease (CKD) BMI 27 with a history of pre-diabetes, myocardial infarction, stroke, or peripheral artery disease (PAD) The program covers the following GLP-1 receptor agonists: Foundayo (orforglipron) tablet, all dose strengths and formulations Wegovy (semaglutide) injections and tablets, all dose strengths and formulations Zepbound (tirzepatide) injections, only when prescribed as the KwikPen (single-dose vials and other single-dose pen formats are excluded) All prescriptions require prior authorization through Humana, which oversees clinical review to ensure adherence to the program's strict medical-necessity guidelines
Formation and stability of anthocyanins-loaded nanocomplexes prepared with chitosan hydrochloride and carboxymethyl chitosan
The brand positions NAD+ for cellular energy support, vitality, and healthy-aging support
patients should use alternative contraception for 4 weeks after initiation and each dose escalation [1] Pregnancy/lactation : Tirzepatide for weight management should be discontinued when pregnancy is recognized due to potential fetal risk
Among several radiolabel types, fluorine-18 is one of the most favorable radioisotopes for nuclear medicine imaging owing to its low positron emission energy and potential for high resolution and wide use in todays clinical settings 16,18
US$ 29.34
US$ 29.86
US$ 27.95
US$ 24.69
